脑膜瘤蛋白质组分析揭示临床相关分子模式
本研究采用液相色谱串联质谱技术,对61例涵盖所有WHO级别及不同临床侵袭性的脑膜瘤FFPE样本进行全局蛋白质定量,共鉴定3042种独特蛋白。无监督聚类显示凸面与颅底脑膜瘤存在蛋白质组和通路差异;高级别肿瘤富集特定癌基因;无论WHO级别,快速复发(<3年)者呈现mRNA加工和基质复合体激活受损模式。大肿瘤(>3cm)和放疗暴露者分别显示促增殖和代谢/炎症通路扰动。
要点
- 脑膜瘤不同WHO级别和临床参数呈现独特蛋白质组谱。
- 快速复发(<3年)肿瘤独立于WHO级别,显示mRNA加工和基质复合体激活受损。
- 凸面与颅底脑膜瘤在Notch和PI3K/AKT/mTOR等通路上存在差异。
核心结论
- 不同级别和临床参数的脑膜瘤具有独特蛋白质组谱,可能有助于预测预后和个体化治疗靶点。
研究设计与样本
- 采用液相色谱串联质谱Orbitrap质量分析仪,对61例临床注释良好的FFPE脑膜瘤队列(涵盖所有WHO级别及不同临床侵袭性)进行全局蛋白质丰度定量。
主要发现
- 共定量3042种独特蛋白。
- 无监督聚类显示凸面与颅底脑膜瘤间有106种蛋白差异(Welch t检验,P<0.01)及Notch、PI3K/AKT/mTOR等通路差异。
- 良性(I级)与不典型/恶性(II-III级)脑膜瘤模式不同,高级别病变富集特定癌基因。
- 快速复发(<3年)的临床侵袭性脑膜瘤独立于WHO级别,蛋白模式汇聚于mRNA加工和基质复合体激活受损。
- 较大脑膜瘤(最大径>3cm)和既往放疗暴露者分别显示促增殖(如EGFR)和代谢(线粒体活性)及炎症(干扰素)通路扰动。
临床怎么用
- 蛋白质组特征可能辅助预测脑膜瘤患者预后。
- 差异蛋白和通路或可提名个体化治疗新靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningiomas represent one of the most common brain tumors and exhibit a clinically heterogeneous behavior, sometimes difficult to predict with classic histopathologic features. While emerging molecular profiling efforts have linked specific genomic drivers to distinct clinical patterns, the proteomic landscape of meningiomas remains largely unexplored. METHODS: We utilize liquid chromatography tandem mass spectrometry with an Orbitrap mass analyzer to quantify global protein abundances of a clinically well-annotated formalin-fixed paraffin embedded (FFPE) cohort (n = 61) of meningiomas spanning all World Health Organization (WHO) grades and various degrees of clinical aggressiveness. RESULTS: In total, we quantify 3042 unique proteins comparing patterns across different clinical parameters. Unsupervised clustering analysis highlighted distinct proteomic (n = 106 proteins, Welch's t-test, P < 0.01) and pathway-level (eg, Notch and PI3K/AKT/mTOR) differences between convexity and skull base meningiomas. Supervised comparative analyses of different pathological grades revealed distinct patterns between benign (grade I) and atypical/malignant (grades II‒III) meningiomas with specific oncogenes enriched in higher grade lesions. Independent of WHO grade, clinically aggressive meningiomas that rapidly recurred (<3 y) had distinctive protein patterns converging on mRNA processing and impaired activation of the matrisome complex. Larger sized meningiomas (>3 cm maximum tumor diameter) and those with previous radiation exposure revealed perturbed pro-proliferative (eg, epidermal growth factor receptor) and metabolic as well as inflammatory response pathways (mitochondrial activity, interferon), respectively. CONCLUSIONS: Our proteomic study demonstrates that meningiomas of different grades and clinical parameters present distinct proteomic profiles. These proteomic variations offer potential future utility in helping better predict patient outcome and in nominating novel therapeutic targets for personalized care.
引用
- Papaioannou MD, Djuric U, Kao J, et al. Proteomic analysis of meningiomas reveals clinically distinct molecular patterns. Neuro Oncol. 2019. PMID: 31077268. doi:10.1093/neuonc/noz084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。